Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 8, 2014, Pages e549-e552

  Wang, Zhihong J ^a   Altonok, Deniz ^a   Sood, Sandeep ^a   Konski, Andre ^a   Poulik, Janet ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Children; Diffuse intrinsic pontine glioma (DIPG); High grade glioma; Temozolomide

Indexed keywords

DEXAMETHASONE; LOMUSTINE; TEMOZOLOMIDE; VALPROIC ACID; ALKYLATING AGENT; DACARBAZINE;

ARTICLE; ASTROCYTOMA; ATAXIA; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER RADIOTHERAPY; CASE REPORT; CAUCASIAN; CHILD; DEATH; DIPLOPIA; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; FACIAL NERVE PARALYSIS; FOLLOW UP; HEADACHE; HUMAN; IMAGE ANALYSIS; LOW DRUG DOSE; MALE; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PONTINE GLIOMA; PRESCRIPTION; SCHOOL CHILD; SIGNAL DETECTION; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR RECURRENCE; ANALOGS AND DERIVATIVES; BRAIN STEM NEOPLASMS; DOSE RESPONSE; FATALITY; GLIOMA; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN STEM NEOPLASMS; CHILD; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATAL OUTCOME; GLIOMA; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 84918500005     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000162     Document Type: Article

References (20)

1. Massimino M, Bode U, Biassoni V, et al. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther. 2011;11:247-256.
2. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011;13:410-416.
3. Broniscer A, Chintagumpala M, Fouladi M, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006;76:313-319.
4. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
5. Stupp R, Tonn JC, Brada M, et al. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v190-v193.
6. Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011;13:317-323.
7. Broniscer A, Iacono L, Chintagumpala M, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer. 2005;103:133-139.
8. Brandes AA, Franceschi E. Neuro-oncology: genetic variation in pediatric and adult brain tumors. Nat Rev Neurol. 2010;6:653-654.
9. Spence AM, Kiem HP, Partap S, et al. Complications of a temozolomide overdose: a case report. J Neurooncol. 2006;80:57-61.
10. Koch D, Wick W. Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. J Neurooncol. 2006;77:219-220.
11. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer. 1998;78:652-661.
12. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189-4199.
13. Kokkinakis DM, Bocangel DB, Schold SC, et al. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1, 3-bis (2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res. 2001;7:421-428.
14. Weiler M, Hartmann C, Wiewrodt D, et al. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys. 2010;77:670-676.
15. Kesari S, Schiff D, Drappatz J, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009;15:330-337.
16. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009;11:69-79.
17. Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008;113:2152-2157.
18. Baruchel S, Diezi M, Hargrave D, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer. 2006;42:2335-2342.
19. Horton TM, Thompson PA, Berg SL, et al. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007;25:4922-4928.
20. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-1011.